2. Peptides
  3. Peptide and Derivatives
  4. Inhibitors and Substrates Therapeutic Peptides
  5. Cibinetide

Cibinetide (ARA290) is an EPO-derivative, acting as a specific agonist of erythropoietin/CD131 heteroreceptor, and used for neurological disease treatment.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Cibinetide Chemical Structure

Cibinetide Chemical Structure

CAS No. : 1208243-50-8

Size Price Stock Quantity
5 mg USD 220 In-stock
10 mg USD 350 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 6 publication(s) in Google Scholar

Cibinetide Related Antibodies

Top Publications Citing Use of Products

    Cibinetide purchased from MedChemExpress. Usage Cited in: Toxicol In Vitro. 2020 Aug;66:104864.  [Abstract]

    Representative photomicrographs demonstrate the results of the TUNEL assay. Alterations in apoptotic cells are assessed using the ratio of green fluorescence. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Cibinetide (ARA290) is an EPO-derivative, acting as a specific agonist of erythropoietin/CD131 heteroreceptor, and used for neurological disease treatment.

    In Vitro

    Cibinetide (ARA290) enhances the proliferation, migration, and resistance to H2O2-induced apoptosis of endothelial colony-forming cells (ECFCs)[1]. Cibinetide (ARA290) is an EPO-analog peptide without hematopoietic side-effects but may have neurotrophic and antidepressant effects[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Cibinetide Related Antibodies
    In Vivo

    After ECFC transplantation to mice with CLI, a single Cibinetide (ARA290) injection enhances the ischemic/non-ischemic ratio of hindlimb blood flow and capillary density after 28 days and the homing of radiolabeled transplanted cells to the ischemic leg 4?h after transplantation[1]. Cibinetide (ARA290; 30 μg/kg, s.c.) prevents progressive worsening of glucose control without affecting body weight of rats. Cibinetide significantly decreases glucose AUCs in IPGTT in GK rats[2]. Low-dosage Cibinetide (35 μg/kg, i.p.) treatment only slightly attenuates the EAE severity in rats. Cibinetide-treating group (70 μg/kg, i.p.) significantly delays the onset, decreases the neurologic severity and shortens the duration of EAE in a dose-dependent way[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Molecular Weight

    1257.31

    Formula

    C51H84N16O21
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    Sequence

    {Glp}-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
    Sequence Shortening

    {Glp}-EQLERALNSS
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    Sealed storage, away from moisture

    Powder -80°C 2 years
    -20°C 1 year

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    Solvent & Solubility
    In Vitro: 

    H2O : 66.67 mg/mL (53.03 mM; adjust pH to 8 with NH3·H2O)

    0.1 M NaOH : ≥ 50 mg/mL (39.77 mM)

    DMSO : ≥ 34 mg/mL (27.04 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 0.7953 mL 3.9767 mL 7.9535 mL
    5 mM 0.1591 mL 0.7953 mL 1.5907 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 2.5 mg/mL (1.99 mM); Clear solution; Need ultrasonic and warming and heat to 37°C

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Purity & Documentation
    References
    Animal Administration
    [2]

    Diabetic Goto-Kakizaki (GK) rats, originating from Wistar rats, are bred in our department. Normal Wistar (W) rats are used as nondiabetic controls. All animals are about six weeks old and with body weights 100 to 150 g when treatment is initiated. They are kept at 22°C on a reversed 12-h light-dark cycle with free access to food, except when fasted overnight as noted below. Rats are treated over 4 wks with Cibinetide by a once daily subcutaneous (s.c.) injection at a dose of 30 μg/kg body weight or PBS. Blood samples for determination of glucose are taken after a small tail incision and analyzed every week before morning s.c. injection of either Cibinetide or placebo. During the experimental period, body weights are measured weekly.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO / 0.1 M NaOH / H2O 1 mM 0.7953 mL 3.9767 mL 7.9535 mL 19.8837 mL
    5 mM 0.1591 mL 0.7953 mL 1.5907 mL 3.9767 mL
    10 mM 0.0795 mL 0.3977 mL 0.7953 mL 1.9884 mL
    15 mM 0.0530 mL 0.2651 mL 0.5302 mL 1.3256 mL
    20 mM 0.0398 mL 0.1988 mL 0.3977 mL 0.9942 mL
    25 mM 0.0318 mL 0.1591 mL 0.3181 mL 0.7953 mL
    0.1 M NaOH / H2O 30 mM 0.0265 mL 0.1326 mL 0.2651 mL 0.6628 mL
    H2O 40 mM 0.0199 mL 0.0994 mL 0.1988 mL 0.4971 mL
    50 mM 0.0159 mL 0.0795 mL 0.1591 mL 0.3977 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Cibinetide Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Cibinetide1208243-50-8ARA290ARA 290ARA-290OthersInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Cibinetide
    Cat. No.:
    HY-P0168
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.